

10/578590

Attorney's Docket No. 035784/311260

IN THE UNITED STATES DESIGNATED OFFICE (DO/US) MAY 03 MAY 2006

In re: Long *et al.*

Attn: DO/US

International Appl. No.: PCT/US2004/036958

International Filing Date: 04 NOVEMBER 2004

For: METHODS OF THERAPY FOR CANCERS EXPRESSING THE CD40 ANTIGEN

May 3, 2006

Mail Stop PCT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT

Sir:

The patents listed on the attached PTO-1449 were cited in the International Search Report of corresponding International Application No. PCT/US2004/036958. A copy of the Search Report is enclosed for the Examiner's convenience. Applicant encloses copies of any cited foreign patent documents and non-patent literature in accordance with 37 CFR 1.98(a)(2). Note that Cite No. 5, EP 1 391 464 A1, is an English equivalent for Cite No. 1, WO 02/088186 A1.

The Examiner may wish to consider the notations on the Search Report itself regarding the relevance of each item. It is requested that the Examiner consider these references and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

Respectfully submitted,



Leslie T. Henry

Registration No. 45,714

ALSTON & BIRD LLP

Bank of America Plaza

101 South Tryon Street, Suite 4000

Charlotte, NC 28280-4000

Tel Raleigh Office (919) 862-2200


Fax Raleigh Office (919) 862-2260

Customer No. 00826

"Express Mail" Mailing Label Number EV 387075895 US

Date of Deposit: May 3, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop PCT, Attn: DO/US (PTO), Commissioner for Patents, Alexandria, VA 22313-1450.



Lynda Jo Pixley

Substitute for form 1449/PTO (Revised 07/2005) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known		
				Application Number	To Be Assigned	
				Filing Date	Filed Concurrently Herewith	
				First Named Inventor	Long	
				Group Art Unit	To Be Assigned	
Examiner Name	To Be Assigned					
Sheet	1	of	1	Attorney Docket Number	035784/311260	
U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear	
FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
	1	WO 02/088186 A1	11-07-2002	Kirin Beer Kabushiki Kaishai		
	2	WO 02/28904 A2	04-11-2002	Chiron Corporation		
	3	WO 01/83755 A3	11-08-2001	Gemini Science, Inc.		
	4	WO 02/28480 A2	4-11-2002	Chiron Corporation		
	5	EP 1 391 464 A1	02-25-2004	Kirin Beer Kabushiki Kaishai		
OTHER DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				English Language Translation Attached
	6	GISSELBRECHT, C., <i>et al.</i> , "Interleukin-2 Treatment in Lymphoma: A Phase II Multicenter Study," <i>Blood</i> , 1994, pp. 2081-2085, Vol. 83(8).				
	7	ROSENBERG, S.A., <i>et al.</i> , "A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone," <i>The New England Journal of Medicine</i> , 1987, pp. 889-897, Vol. 316(15).				
Examiner Signature				Date Considered		

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.